KPW
RDHL

Kore Private Wealth’s Redhill Biopharma RDHL Stock Holding History

Kore Private Wealth’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1
Closed -$6K – 887
2020
Q2 		$6K Hold
1
– – ﹤0.01% 889
2020
Q1 		$5K Hold
1
– – ﹤0.01% 809
2019
Q4 		$6K Buy
+1
New +$6.39K ﹤0.01% 839

Other funds holding RDHL

DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Kore Private Wealth's RDHL Position: Q3 2020 in Review

Kore Private Wealth sold out of Redhill Biopharma (RDHL) in Q3 2020, closing a stake of 1 share — an estimated $6K sold.

Kore Private Wealth first reported a position in RDHL in Q4 2019 and held it in 3 quarters. The position peaked at $6K in Q2 2020. 47 funds tracked by Wall St. Rank hold RDHL as of Q3 2020.

  • Kore Private Wealth reported no remaining Redhill Biopharma position as of Q3 2020 after selling out during the quarter.
  • Kore Private Wealth sold 1 Redhill Biopharma share in Q3 2020, an estimated $6K.
  • Kore Private Wealth first reported a position in Redhill Biopharma in Q4 2019 and held it in 3 quarters.
  • Kore Private Wealth's Redhill Biopharma position peaked at $6K in Q2 2020.
  • 47 funds tracked by Wall St. Rank held Redhill Biopharma as of Q3 2020.

Based on Kore Private Wealth's 13F filing for Q3 2020, filed 13 Nov 2020.